[Pharmacokinetics of pramiverine in rats, dogs, and monkeys (author's transl)]. 1976

K Steiner, and H W Diekmann, and A Garbe, and H Nowak

The pharmacokinetic properties of 4,4-diphenyl-N-isopropyl-cyclohexylamine-hydrochloride (pramiverine, Sistalgin) in Wistar rats, beagles, and rhesus monkeys are described. After i.v. injection of 14C-labelled pramiverine incorporation of radioactivity from the blood into organs and tissues is rapid. The radioactivity is eliminated from the blood with a half-life of 4-7 h in rats, 17-32 in dogs, and 8-26 h in rhesus monkeys. Unmetabolized pramiverine, in contrast, is eliminated much faster, the half-lives are 2 h in dogs and 3 h in rhesus monkeys. After oral administration maximum serum concentrations are reached after 4 h in rats and dogs and 2 h in rhesus monkeys. The drug undergoes a marked first-pass effect in the liver. In all species pramiverine is absorbed rapidly from the gastro-intestinal tract. Drug and/or metabolites are eliminated in rats and dogs predominantly with feces, in monkeys with urine, independent of the route of administration. During a 6 h interval, biliary elimination was found to be 50% after i.v. and 30% after oral administration. 90% of pramiverine present in the blood plasma is reversibly bound to proteins.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D008297 Male Males
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D003514 Cyclohexylamines A family of alicyclic hydrocarbons containing an amine group with the general formula R-C6H10NH2. Cyclohexylamine
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes

Related Publications

K Steiner, and H W Diekmann, and A Garbe, and H Nowak
April 1976, Arzneimittel-Forschung,
K Steiner, and H W Diekmann, and A Garbe, and H Nowak
April 1976, Arzneimittel-Forschung,
K Steiner, and H W Diekmann, and A Garbe, and H Nowak
April 1976, Arzneimittel-Forschung,
K Steiner, and H W Diekmann, and A Garbe, and H Nowak
April 1976, Arzneimittel-Forschung,
K Steiner, and H W Diekmann, and A Garbe, and H Nowak
January 1982, Arzneimittel-Forschung,
K Steiner, and H W Diekmann, and A Garbe, and H Nowak
August 1988, Journal of pharmaceutical sciences,
K Steiner, and H W Diekmann, and A Garbe, and H Nowak
April 1976, Arzneimittel-Forschung,
K Steiner, and H W Diekmann, and A Garbe, and H Nowak
January 1986, New Jersey medicine : the journal of the Medical Society of New Jersey,
K Steiner, and H W Diekmann, and A Garbe, and H Nowak
January 1984, Drug metabolism and disposition: the biological fate of chemicals,
K Steiner, and H W Diekmann, and A Garbe, and H Nowak
January 1979, Archiv der Pharmazie,
Copied contents to your clipboard!